Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 19/20 | 0.76 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.76 |
| ▸ | F10 | P00742 | 2/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461162 | 0.90 | F2 (0.64) | F2PRSS1F10PRSS2PRSS3 | |
| SCHEMBL7379338 | 0.86 | F2 (1.00) | F2PRSS1F10PRSS2PRSS3 | |
| SCHEMBL29992597 | 0.85 | F2 (0.57) | F2PRSS1F10PRSS2PRSS3 | |
| SCHEMBL23474326 | 0.84 | F2 (0.56) | F2PRSS1 | |
| SCHEMBL23474325 | 0.82 | F2 (0.60) | F2PRSS1F10PRSS2PRSS3 | |
| SCHEMBL7233400 | 0.80 | F2 (0.57) | F2PRSS1F10PRSS2PRSS3 | |
| SCHEMBL23474310 | 0.79 | F2 (0.77) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29904359 | 0.79 | F2 (0.77) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL6295974 | 0.77 | F2 (0.67) | F2PRSS1F10ADRA1BPRSS2 | |
| SCHEMBL7233636 | 0.76 | F2 (0.53) | F2PRSS1F10PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011323-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240391917-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-11-28 | — | — | US | disclosed |
| US-12110288-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4069238-A1 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115052604-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | OMEROS CORPORATION | 2021-09-23 | — | — | US | disclosed |
| WO-2021178902-A1 | METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME | OMEROS CORPORATION (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-17 | — | — | US | disclosed |
| WO-2021113686-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12110288-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | F2 4221/4885PRSS1 159/4885F10 4184/4885 |
| US-20210292436-A1 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | MASP2, ACE2, MAS1 | F2 36/4885PRSS1 244/4885F10 299/4885 |
| US-20210179612-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F2 4221/4885PRSS1 159/4885F10 4184/4885 |
| US-20250011323-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F2 4221/4885PRSS1 159/4885F10 4184/4885 |
| US-20240391917-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | F2 4221/4885PRSS1 159/4885F10 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.